

## Lidocaine Patch

### **Goal(s):**

- Provide coverage only for diagnoses that are supported by the medical literature.
- Restrict use to OHP-funded diagnoses in adults. Allow case-by-case review for members covered under the EPSDT program.

### **Length of Authorization:**

- 90 days to 12 months (criteria specific)

### **Requires PA:**

- Lidocaine Patch

### **Covered Alternatives**

- Current PMPDP preferred drug list per OAR 410-121-0030 at [www.orpdl.org](http://www.orpdl.org)
- Searchable site for Oregon FFS Drug Class listed at [www.orpdl.org/drugs/](http://www.orpdl.org/drugs/)

Approval Criteria		
1. What diagnosis is being treated?	Record ICD10 code	
2. Is the diagnosis supported by evidence for its use in that condition (refer to Table 1 for examples)?	<b>Yes:</b> Go to #3	<b>No:</b> Pass to RPh. Deny; medical appropriateness.
3. Is the diagnosis an OHP-funded diagnosis (refer to Table 1 for examples)?	<b>Yes:</b> Go to # 5	<b>No:</b> If not eligible for EPSDT review: Pass to RPh. Deny; not funded by the OHP  If eligible for EPSDT review: Go to #4.
4. Is there documentation that the condition is of sufficient severity that it impacts the patient's health (e.g., quality of life, function, growth, development, ability to participate in school, perform activities of daily living, etc)?	<b>Yes:</b> Approve for 90 days	<b>No:</b> Pass to RPh. Deny; medical necessity.
5. Is this a request for renewal of a previously approved prior authorization for lidocaine patch?	<b>Yes:</b> Go to <b>Renewal Criteria</b>	<b>No:</b> Go to # 6
6. Is the prescription for Lidoderm patch greater than 3 patches/day?	<b>Yes:</b> Pass to RPh. Deny; medical appropriateness	<b>No:</b> Approve for 90 days

## Renewal Criteria

1. Does the patient have documented improvement from lidocaine patch?

**Yes:** Approve for up to 12 months

**No:** Pass to RPh. Deny for medical appropriateness.

**Table 1. OHP Funded Diagnosis and Evidence Supports Drug Use in Specific Indication**

Condition	Lidocaine Patch
Funded	Evidence Supports Use
Diabetic Neuropathy	X
Postherpetic Neuropathy	X
Painful Polyneuropathy	X
Spinal Cord Injury Pain	
Chemotherapy Induced Neuropathy	
Non-funded	
Fibromyalgia	

P&T Review: 8/20 (DM); 7/18; 3/17  
 Implementation: 4/1/17